Celestra Health Accelerates Clinical Trials and Expands Global Footprint
October 31, 2025
CELESTRA HEALTH SYSTEMS — AI-powered gait analysis software platform for monitoring and managing neurological diseases • celestrahealth.com
Celestra Health Systems continues to advance its mission of redefining how neurological diseases are monitored and managed. The third quarter of 2025 marked major progress across our clinical programs, partnerships, and research collaborations — solidifying our position as a leader in digital biomarker innovation.
In the US, based on our $500K contract with a global pharmaceutical firm, our Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical trial is now fully underway, with stellar results to date. Throughout the trial, we have maintained an exceptionally high adherence rate of 70% and have demonstrated the sensitivity of our platform in detecting subtle changes in disease condition. The pace of participant recruitment has been faster than forecast; patient feedback from the CIDP Foundation International Symposium 2025 held in Denver, Colorado was highly positive.
In Canada, our first longitudinal Parkinson’s disease clinical trial is also fully underway at The Ottawa Hospital, to measure changes in patient condition in response to a novel drug therapy over a 12-month period. To date, we have achieved a “perfect” 100% patient adherence rate.
In Germany, we have now completed the data collection and algorithm development phases of our MS collaboration with the Technical University of Dresden (TUD). By the end of 2025, the validation of our suite of In-Clinic gait assessment tests will be completed, to complement our At-Home patient monitoring capabilities.
On the global stage, the Celestra team participated in ECTRIMS 2025, the world’s largest MS neurology conference, held in Barcelona. We held executive-level meetings with several global pharmaceutical firms and generated over 50 leads spanning 17 countries; in addition, members of our human kinetics PhD team published our research results.
Throughout the quarter, we continued to invest heavily in our Research & Development activities, as we enhanced our algorithms for extracting insights from walking, turning, jumping and stair ascending / descending. We also demonstrated our ability to measure spasticity in MS patients under free living conditions; we believe we are the only company in the world to successfully implement this capability.
Looking ahead, we continue to ramp up our business development activities in the US and Europe, as we capitalize on strong levels of interest from pharmaceutical firms, research institutes and neurology clinics to build our sales pipeline and translate leads to paying customers. Further to our FDA Software as a Medical Device (SaMD) Class II designation, we are preparing our submission to achieve European regulatory compliance. Preparations are also underway for a seed investment round by early 2026 to fuel our global sales expansion.
To learn more, visit celestrahealth.com